Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9- aminocamptothecin in adult cancer patients

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1492-1501

  Takimoto, C H ^a   Dahut, W ^a   Marino, M T ^a   Nakashima, H ^a   Liang, M D ^a   Harold, N ^a   Lieberman, R ^a   Arbuck, S G ^a   Band, R A ^a   Chen, A P ^a   Hamilton, J M ^a   Cantilena, L R ^a   Allegra, C J ^a   Grem, J L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG STRUCTURE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER;

EID: 0030905494     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1492     Document Type: Article

References (26)

1. Potmesil M: Camptothecins from bench research to hospital wards. Cancer Res 54:1431-1439, 1994
2. Burris HA, Fields SM: Topoisomerase I inhibitors: An overview of the camptothecin analogs. Hematol Oncol Clin North Am 8:333-355, 1994
3. Takimoto CH, Arbuck SG: The Camptothecins, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott-Raven, 1996, pp 463-484
4. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
5. Pantazis P, Hinz HR, Mendoza JT, et al: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980-3987, 1992
6. Rubin E, Wood V, Bharti A, et al: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276, 1995
7. Dahut W, Harold N, Takimoto C, et al: A phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14:1236-1244, 1996
8. Wilson WH, Pearson D, Humphrey R, et al: A phase II and dose escalation study ± G-CSF of 9-amino-camptothecin (9-AC) in relapsed lymphoma. Ann Oncol 7:131, 1996 (suppl 7; abstr)
9. Hertzberg RP, Caranfa MJ, Holden, et al: Modification of the hydroxy lactone ring of camptothecins: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-720, 1989
10. Fassberg J, Stella VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676-684, 1992
11. Takimoto CH, Klecker RW, Dahut WL, et al: Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J ChromatogrB Biomed Appl 655:97-104, 1994
12. Gupta E, Letingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994
13. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982, p 321
14. Perrier D, Mayersohn M: Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 71:372-373, 1982
15. Beal SL, Sheiner LB: NONMEM Project Group (ed 2.1). San Francisco, CA, University of California, San Francisco, 1989
16. Rowland M, Tozer T: Clinical Pharmacokinetics: Concepts and Applications (ed 3). Philadelphia, PA, Williams & Wilkins, 1995, p 173
17. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970
18. Rowland M, Tozer T: Clinical Pharmacokinetics: Concepts and Applications (ed 3). Philadelphia, PA, Williams & Wilkins, 1995, p 341
19. Stewart CF, Baker SD, Heideman RL, et al: Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946-1954, 1994
20. Burke TG, Mi Z: Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36:2580-2582, 1993
21. Blaney SM, Balis FM, Cole DE, et al: Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 53:1032-1036, 1993
22. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperdino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) administered as a 90 minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
23. Rothenberg ML, Kuhn JG, Burris HA, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
24. Rivory LP, Chateleut E, Canal P, et al: Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 54:6330-6333, 1994
25. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
26. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Disp 20:706-713, 1992